ISSN: 1300-7777 E-ISSN: 1308-5263
The effects of platelet receptor GPIIb/IIIa polymorphism (Leu Pro33) on the receptor expression and platelet aggregation in patients with ischaemic stroke [Turk J Hematol]
Turk J Hematol. 2007; 24(4): 155-163

The effects of platelet receptor GPIIb/IIIa polymorphism (Leu Pro33) on the receptor expression and platelet aggregation in patients with ischaemic stroke

Endre Pongrácz1, Katalin Schweitzer2, József Furész2, János Fent2, Attila Tordai3, Zoltán Nagy4
1Department Of Neurology, Stroke Unit, Central Hospital Of Home Office, Budapest, Hungary
2Department Of Pathophisiology, Institute Of Health Protection, Hungarian Defence Forces, Budapest, Hungary
3Department Of Molecular Genetics, National Institute Of Haemathology, Budapest, Hungary
4Department Of Vascular Neurology, National Stroke Centre, Semmelweis University, Budapest, Hungary

Platelet hyperaggregation in ischaemic stroke patients is a proven finding, and associated with increased expression of the platelet surface GPIIb/IIIa receptor. The polymorphism occurs at nucleotide position 1565 of the GPIIIa gene resulting a 33Leu-Pro change. Data are conflicting regarding the abnormal function of the PlA1/A2 receptor in stroke. The aim of the study was to address the difference of platelet receptor function in ischemic stroke patients with the wild PlA1/A1 and heterozygous PlA1/A2 genotype. A total of 51 patients with PA1/A1 and 54 patients with PlA1/A2 genotypes were enrolled. Polymerase chain
reaction was used for genotyping of platelets. Platelet aggregation was measured in whole blood and in platelet rich plasma (PRP). Flow cytometry was used for measuring surface molecule expression (CD42b, CD41a, CD61, CD62P) and fibrinogen binding capacity of cells with phosphate buffer solution (PBS) in comparison with activation by ristocetin in whole blood as well as by adenosine diphosphate (ADP) in PRP. In comparison with wild types, platelets carrying the PlA1/A2 genotypes showed hyperaggregation measured
in whole blood and induced by ristocetin (p< 0.05). Using whole blood flow cytometry with ristocetin induction, the CD62P+/FIB- (P selectin) and the CD62P+/FIB+ were more expressed in heterozygous platelets as compared to wild types (p< 0.01 and p< 0.05), respectively. According to mean fluorescence intensity with ADP induction, an increased expression of CD61+, CD61+/CD41+ and CD62P+ in PlA1/A2 platelets were detected
as compared to the group carrying the wild type (p< 0.0001, p= 0.006, p= 0.0001), respectively. These findings support the possibility that in ischaemic stroke patients, platelets carrying PlA1/A2 genotypes can be activated by different inductors in a way, which leads to permanent hyperfunction of platelet surface receptor GPIIIa.

Keywords: Genetic polymorphism, platelet, GPIIb/IIIa polymorphism (Leu33Pro), arterial thrombosis, ischaemic stroke, genetic risk factors


Endre Pongrácz, Katalin Schweitzer, József Furész, János Fent, Attila Tordai, Zoltán Nagy. The effects of platelet receptor GPIIb/IIIa polymorphism (Leu Pro33) on the receptor expression and platelet aggregation in patients with ischaemic stroke. Turk J Hematol. 2007; 24(4): 155-163

Corresponding Author: Endre Pongrácz, Hungary


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686